Late Breaking Abstract - DESTINATION: tezepelumab long-term safety and efficacy versus placebo in patients with severe, uncontrolled asthma
A. Menzies-Gow (London, United Kingdom), M. Wechsler (Denver, CO, United States), C. Brightling (Leicester, United Kingdom), S. Korn (Heidelberg, Germany), A. Bednarczyk (Warsaw, Poland), S. Ponnarambil (Cambridge, United Kingdom), G. Almqvist (Gothenburg, Sweden), K. Lawson (Cambridge, MA, United States), S. Caveney (Thousand Oaks, CA, United States), K. Bowen (Gaithersburg, MD, United States), G. Colice (Gaithersburg, MD, United States)
Source: International Congress 2022 – Pearls in airway immunology: from mouse to man
Session: Pearls in airway immunology: from mouse to man
Session type: Oral Presentation
Number: 9002
   
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
A. Menzies-Gow (London, United Kingdom), M. Wechsler (Denver, CO, United States), C. Brightling (Leicester, United Kingdom), S. Korn (Heidelberg, Germany), A. Bednarczyk (Warsaw, Poland), S. Ponnarambil (Cambridge, United Kingdom), G. Almqvist (Gothenburg, Sweden), K. Lawson (Cambridge, MA, United States), S. Caveney (Thousand Oaks, CA, United States), K. Bowen (Gaithersburg, MD, United States), G. Colice (Gaithersburg, MD, United States). Late Breaking Abstract - DESTINATION: tezepelumab long-term safety and efficacy versus placebo in patients with severe, uncontrolled asthma. 9002
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|